These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 15247960

  • 21. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy.
    Sampietro T, Bigazzi F, Rossi G, Dal Pino B, Puntoni MR, Sbrana F, Chella E, Bionda A.
    J Intern Med; 2005 Jun; 257(6):523-30. PubMed ID: 15910556
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [Abstract] [Full Text] [Related]

  • 27. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
    Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J, ACTFAST investigators.
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):168-74. PubMed ID: 17053166
    [Abstract] [Full Text] [Related]

  • 28. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
    Nawawi H, Osman NS, Yusoff K, Khalid BA.
    Horm Metab Res; 2003 Aug; 35(8):479-85. PubMed ID: 12953165
    [Abstract] [Full Text] [Related]

  • 29. Atorvastatin affects C-reactive protein levels in patients with coronary artery disease.
    Karaca I, Ilkay E, Akbulut M, Yavuzkir M, Pekdemir M, Akbulut H, Arslan N.
    Curr Med Res Opin; 2003 Aug; 19(3):187-91. PubMed ID: 12803732
    [Abstract] [Full Text] [Related]

  • 30. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 31. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
    Kadoglou NP, Vrabas IS, Kapelouzou A, Lampropoulos S, Sailer N, Kostakis A, Liapis CD.
    Regul Pept; 2011 Oct 10; 170(1-3):57-61. PubMed ID: 21640762
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 10; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 35. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C, Athyros V, Gaw A, ACTFAST-2 investigators and Steering Committee members.
    Curr Med Res Opin; 2007 Aug 10; 23(8):1945-56. PubMed ID: 17626713
    [Abstract] [Full Text] [Related]

  • 36. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J, ACTFAST investigators.
    Am Heart J; 2007 May 10; 153(5):881-8. PubMed ID: 17452168
    [Abstract] [Full Text] [Related]

  • 37. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
    Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB.
    Am Heart J; 2006 Nov 10; 152(5):982.e1-5. PubMed ID: 17070175
    [Abstract] [Full Text] [Related]

  • 38. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
    Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F.
    Circulation; 2005 Feb 01; 111(4):412-9. PubMed ID: 15687128
    [Abstract] [Full Text] [Related]

  • 39. Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholesterolemic rabbits.
    Zhang D, Che D, Zhao S, Sun Y.
    J Cardiovasc Pharmacol; 2007 Sep 01; 50(3):281-5. PubMed ID: 17878756
    [Abstract] [Full Text] [Related]

  • 40. Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients.
    Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y.
    Int J Cardiol; 2004 Mar 01; 94(1):111-7. PubMed ID: 14996484
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.